Nuwellis, INC 10-Q quarterly reports

Nuwellis reports Q1 2026 revenue growth of 26.2% alongside the acquisition of Rendiatech to expand its cardiorenal platform.

Nuwellis, Inc. reported a widened net loss for the nine months ended September 30, 2025, alongside strategic realignments including exiting international operations and terminating a clinical trial, while actively raising capital.

Nuwellis, Inc. reported a wider net loss in Q2 2025, implemented a reverse stock split, and exited international operations while terminating a clinical trial to focus on core U.S. markets.

Nuwellis, Inc. reports its financial results for the first quarter of 2025, highlighting a slight increase in net sales but continued losses and efforts to secure additional capital.

Nuwellis, a medical device company, announced its Q3 2024 results, showing a slight decrease in net sales but a significant improvement in net income due to warrant liability adjustments, while also detailing cost-cutting measures and recent capital raising activities.

Nuwellis, Inc. announces its Q2 2024 financial results, highlighting a slight increase in net sales but significant losses and ongoing efforts to address financial instability.

Nuwellis, Inc. reports a net loss for Q1 2024, while implementing cost-cutting measures and securing additional funding through a public offering.